SY-12696
/ Shouyao Holdings
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 26, 2025
SY-12696, a novel and potent MALT1 protease inhibitor, for the treatment of B-cell lymphomas
(AACR 2025)
- "Based on current studies, SY-12696 has demonstrated significant inhibitory potency on ABC-DLBCL cancer cells in vitro and in vivo, which makes SY-12696 a promising candidate for further development as a monotherapy or in combination with BTKi to treat relapsed/refractory B-cell lymphoma, particularly those resistance to BTKi."
B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Extranodal Marginal Zone Lymphoma • Hematological Malignancies • Lymphoma • Marginal Zone Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CARD11 • CD79A • MALT1 • MYD88
1 to 1
Of
1
Go to page
1